Single-nucleotide polymorphisms (SNPs) associated with recurrence and survival in patients with early-stage non-small cell lung cancer
| Gene-SNP by outcome | Location | Model | Discovery | Validation | Meta-analysis* | P_het | |||
| HR (95% CI)† | P value | HR (95% CI)† | P value | HR (95% CI)† | P value | ||||
| Recurrence | |||||||||
| TRB: rs1964986‡ | Intron | REC | 1.56 (1.04 to 2.34) | 2.99E-02 | 2.36 (1.44 to 3.85) | 6.00E-04 | 1.84 (1.35 to 2.52) | 1.15E-04 | 0.20 |
| IL2RB: rs3218339 | Intron | DOM | 1.53 (1.08 to 2.18) | 1.75E-02 | 1.91 (1.23 to 2.96) | 3.93E-03 | 1.67 (1.27 to 2.20) | 2.55E-04 | 0.45 |
| SYK: rs10761395 | Intron | REC | 1.81 (1.17 to 2.82) | 8.01E-03 | 1.86 (1.06 to 3.26) | 2.95E-02 | 1.83 (1.30 to 2.59) | 6.03E-04 | 0.94 |
| TRA: rs7155927 | Intron | DOM | 0.58 (0.37 to 0.92) | 2.13E-02 | 0.52 (0.30 to 0.91) | 2.12E-02 | 0.56 (0.39 to 0.79) | 1.18E-03 | 0.75 |
| CD4: rs3782736‡ | Intron | REC | 0.62 (0.42 to 0.92) | 1.79E-02 | 0.54 (0.32 to 0.93) | 2.49E-02 | 0.59 (0.43 to 0.81) | 1.20E-03 | 0.71 |
| TRB: rs1573618‡ | Intron | ADD | 0.80 (0.64 to 1.00) | 4.65E-02 | 0.73 (0.55 to 0.98) | 3.84E-02 | 0.77 (0.65 to 0.92) | 4.52E-03 | 0.66 |
| PDCD1LG2: rs7854413‡ | missense | DOM | 0.64 (0.40 to 1.00) | 4.91E-02 | 0.50 (0.27 to 0.95) | 3.38E-02 | 0.59 (0.41 to 0.85) | 4.61E-03 | 0.56 |
| Survival | |||||||||
| IDO1: rs10108662‡ | Intron | REC | 1.49 (1.01 to 2.21) | 4.49E-02 | 2.47 (1.60 to 3.80) | 3.98E-05 | 1.87 (1.40 to 2.51) | 2.17E-05 | 0.09 |
| CUL1: rs122571 | Intron | ADD | 0.79 (0.65 to 0.96) | 1.71E-02 | 0.66 (0.51 to 0.86) | 1.79E-03 | 0.74 (0.63 to 0.87) | 1.61E-04 | 0.27 |
| GRB2: rs959260 | Intron | DOM | 1.39 (1.05 to 1.84) | 2.11E-02 | 1.79 (1.24 to 2.60) | 2.00E-03 | 1.52 (1.22 to 1.90) | 2.13E-04 | 0.28 |
| CUL1: rs243538‡ | Intron | ADD | 0.75 (0.61 to 0.93) | 7.54E-03 | 0.74 (0.56 to 0.98) | 3.30E-02 | 0.75 (0.63 to 0.88) | 6.32E-04 | 0.94 |
| GRB2: rs4789182‡ | Intron | DOM | 1.31 (1.00 to 1.72) | 4.50E-02 | 1.67 (1.16 to 2.41) | 5.00E-03 | 1.43 (1.15 to 1.77) | 1.13E-03 | 0.29 |
| TRB: rs1573618‡ | Intron | ADD | 0.82 (0.68 to 0.99) | 4.26E-02 | 0.71 (0.54 to 0.93) | 1.38E-02 | 0.79 (0.67 to 0.92) | 2.14E-03 | 0.39 |
| JAK1: rs4915675 | Intron | REC | 1.67 (1.02 to 2.72) | 4.02E-02 | 1.91 (1.07 to 3.43) | 2.94E-02 | 1.91 (1.07 to 3.43) | 2.96E-03 | 0.73 |
*The meta-analysis was based on a fixed-effects model.
†HR was adjusted for age, gender, smoking status, tumor stage, performance status and treatment.
‡Data for rs2855983 and rs10975179 were not shown owing to their strong linkage with rs1964986 and rs7854413 (r2 >0.8), respectively. In the validation phase, data for rs1964986, rs3782736, rs1573618, rs10108662, rs243538, and rs4789182 were replaced by linked SNPs (r2 >0.8) rs10273639, rs10849524, rs6464489, rs7820268, rs243519, and rs9944529, respectively.
ADD, additive; DOM, dominant; P het, p test for heterogeneity; REC, recessive.